

CITATION REPORT

List of articles citing

Fc γ RIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc γ RIIIa, Independently of the Fc γ RIIIa-48L/R/H Phenotype

DOI: 10.1182/blood.v90.3.1109
Blood, 1997, 90, 1109-1114.

Source: <https://exaly.com/paper-pdf/28466580/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
680	IgG receptor polymorphisms: risk factors for disease. 1998 , 48, 222-32		205
679	A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. 1998 , 74 Suppl 2, 375-83		25
678	The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. 1998 , 41, 1813-8		121
677	Variant Genotypes of the Low-Affinity FcγReceptors in Two Control Populations and a Review of Low-Affinity FcγReceptor Polymorphisms in Control and Disease Populations. <i>Blood</i> , 1999 , 94, 4220-4232 ^{2,2}		159
676	Relevance of Fc gamma RIIIa-158V-F polymorphism to recurrence of adult periodontitis in Japanese patients. 1999 , 117, 350-4		47
675	Association of Fc gamma receptor IIIB, but not of Fc gamma receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese. 1999 , 1, 53-60		107
674	Altered distribution of Fcγ receptor IIIA alleles in a cohort of Korean patients with lupus nephritis. 1999 , 42, 818-9		50
673	Sustained response to doxycycline therapy in two patients with SAPHO syndrome. 1999 , 42, 819-21		35
672	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. 1999 , 42, 822-3		79
671	Mining variations in genes of innate and phagocytic immunity: current status and future prospects. 2000 , 7, 9-15		14
670	Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis. 2000 , 43, 735-9		116
669	Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. 2000 , 43, 2328-34		93
668	Fcγ receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. 2000 , 43, 2793-800		98
667	Comparison of flow cytometric assays with isotopic assays of (51)chromium-labeled cells for estimation of red cell clearance or survival in vivo. 2000 , 40, 228-39		14
666	Variations in genes encoding neutrophil antigens NA1 and NA2. 2000 , 40, 645-53		29
665	A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. 2000 , 242, 127-32		72
664	Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. <i>Blood</i> , 2000 , 95, 2386-2390	2.2	55

663	The Fcγ receptor genotype as a risk factor for generalized early-onset periodontitis in Japanese patients. 2000 , 71, 1425-32		68
662	Genetics of systemic lupus erythematosus. Clinical implications. 2000 , 26, 229-56, v-vi		63
661	FcγRIIc 13Q/STP polymorphism influences the antibody-dependent cytotoxicity levels triggered by natural killer cells against pig aortic endothelial cells. 2001 , 33, 333		4
660	Ig-binding receptors on human NK cells as effector and regulatory surface molecules. 2001 , 20, 371-414		55
659	High resolution mapping of the binding site on human IgG1 for Fc γRI, Fc γRII, Fc γRIII, and FcRn and design of IgG1 variants with improved binding to the Fc γRI. 2001 , 276, 6591-604		864
658	The Fc γ receptor genotype as a severity factor for chronic periodontitis in Japanese patients. 2001 , 72, 1324-31		64
657	Meta-analysis of the association between low-affinity Fcγ receptor gene polymorphisms and hematologic and autoimmune disease. <i>Blood</i> , 2001 , 98, 1634-5	2.2	37
656	Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. 2001 , 113, 596-9		68
655	Involvement of Fc γ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. 2001 , 115, 125-30		46
654	Fcγ receptors in autoimmune diseases. 2001 , 31, 821-31		38
653	Fcγ receptor polymorphisms in populations in Ethiopia and Norway. <i>Immunology</i> , 2001 , 104, 87-91/7.8		25
652	The Fcγ receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. 2001 , 44, 618-25		72
651	Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. 2001 , 44, 739-50		143
650	Polymorphisms of Fc γ-receptors RIIa, RIIIa, and RIIIb in patients with adult periodontal diseases. 2001 , 2, 258-62		45
649	Identification of the CD32/FcγRIIc-Q13/STP13 polymorphism using an allele-specific restriction enzyme digestion assay. 2001 , 258, 85-95		12
648	Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease. 2001 , 184, 1548-55		89
647	Engineering antibodies for therapy. 2002 , 3, 237-56		74
646	Fcγ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. 2002 , 61, 786-92		60

645	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. <i>Blood</i> , 2002 , 99, 754-8	2.2	1607
644	Fc gamma receptor genes as risk markers for localized aggressive periodontitis in African-Americans. 2002 , 73, 517-23		35
643	Monoclonal anti-D development programme. 2002 , 10, 199-204		24
642	Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease. 2002 , 69, 109-14		9
641	Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. 2002 , 46, 1242-54		268
640	Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. 2002 , 46, 1563-71		168
639	Synonymous nucleotide substitutions in the neonatal Fc receptor. 2002 , 54, 139-40		3
638	Fcgamma receptor IIIA polymorphism in Korean patients with systemic lupus erythematosus. 2002 , 21, 222-6		16
637	Interaction sites on human IgG-Fc for FcgammaR: current models. 2002 , 82, 57-65		184
636	Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. 2002 , 277, 26733-40		1279
635	Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. 2003 , 21, 3940-7		1112
634	Distribution of variant genotypes of Fc gamma receptor IIIa in healthy Chinese population of Zhengzhou City. 2003 , 23, 239-41		2
633	Evidence for non-random distribution of Fcgamma receptor genotype combinations. 2003 , 55, 240-6		52
632	Natural killer receptor repertoires in transplantation. 2003 , 30, 169-76		7
631	The mechanisms of action of rituximab in the elimination of tumor cells. 2003 , 30, 3-8		166
630	Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. 2003 , 144, 143-7		22
629	Mechanism of action and resistance to monoclonal antibody therapy. 2003 , 30, 424-33		71
628	Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. 2003 , 277, 185-92		49

627	The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. 2003 , 48, 455-9	375
626	Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCγ receptor type IIA alleles. 2003 , 48, 460-70	68
625	FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. 2003 , 61, 189-202	228
624	Association of Fcγ receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. 2003 , 61, 374-83	128
623	Fcγ receptor polymorphisms in relation to periodontitis. 2003 , 30, 595-602	54
622	The genetic relationship to periodontal disease. 2003 , 32, 36-49	42
621	Fcγ receptors in the initiation and progression of systemic lupus erythematosus. 2003 , 81, 382-9	17
620	Impact of genetic polymorphisms on the smoking-related risk of periodontal disease: the population-based study SHIP. 2003 , 1, 197	6
619	The Fc γ RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. 2003 , 63, 1475-82	110
618	Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. 2003 , 120, 135-41	60
617	Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcγ RIIIA (CD16). 2003 , 132, 81-6	27
616	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. 2003 , 22, 7359-68	578
615	Factors predicting the response to rituximab in indolent lymphoma. 2003 , 4, 19-21	1
614	Risk of periodontitis in systemic lupus erythematosus is associated with Fcγ receptor polymorphisms. 2003 , 74, 378-84	45
613	Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. 2003 , 42, 446-52	47
612	FcγRIIIA-158V and rheumatoid arthritis: a confirmation study. 2003 , 42, 528-33	40
611	Pharmacogenetics in cancer treatment. 2003 , 54, 437-52	100
610	Role of Fcγ receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. 2003 , 25 Suppl 1, S14-8	49

609	Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. 2004 , 64, 4664-9	356
608	Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. 2004 , 10, 2253-64	145
607	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. 2004 , 5, 1107-16	6
606	Immune-mediated hemolytic anemia. 2004 , 2004, 48-62	40
605	The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. 2004 , 10, 7529-39	131
604	Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. 2004 , 22, 4717-24	169
603	Association of Fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. 2004 , 63, 21-7	120
602	Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. 2004 , 19, 511-9	166
601	Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. 2004 , 127, 561-7	52
600	Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. 2004 , 138, 183-92	88
599	Interleukin-4 gene polymorphisms in Japanese and Caucasian patients with aggressive periodontitis. 2004 , 31, 384-9	37
598	Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis. 2004 , 5, 130-7	53
597	Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis. 2004 , 5, 521-9	26
596	Fc gamma receptors are critical modulators of inflammation within the synovium: comment on the article by Blom et al. 2004 , 50, 1352-3; author reply 1353-4	
595	Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. 2004 , 87, 614-22	453
594	Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy. 2004 , 77, 319	28
593	Fc gamma receptors. 2004 , 92, 199-205	78
592	From the bench to the bedside: ways to improve rituximab efficacy. <i>Blood</i> , 2004 , 104, 2635-42	2.2 443

591	Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. 2004 , 10, 6248-55		208
590	Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. 2004 , 6, R557-62		40
589	Ex vivo expansion of natural killer cells for clinical applications. 2004 , 6, 15-22		88
588	Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. 2004 , 336, 1239-49		280
587	Immunobiology of natural killer lymphocytes in transplantation. 2004 , 78, 1-6		20
586	Genomic polymorphisms in sepsis. 2004 , 32, 569-79		173
585	A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaRIIIA genes. <i>Blood</i> , 2004 , 103, 4028-35	2.2	69
584	Fc gamma RIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004 , 103, 1472-4	2.2	181
583	The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. <i>Blood</i> , 2004 , 104, 2791-3	2.2	46
582	Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?. 2005 , 25, 435-40		12
581	Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. 2005 , 5 Suppl 1, S37-47		87
580	The association between fcgammaRIIIB polymorphisms and systemic lupus erythematosus in Korea. 2005 , 14, 346-50		23
579	Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. 2005 , 21, 1644-52		299
578	Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. <i>Immunology</i> , 2005 , 115, 416-21	7.8	17
577	IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. 2005 , 139, 542-50		70
576	Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism. 2005 , 306, 128-36		16
575	IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. 2005 , 306, 151-60		186
574	IgG Fc receptor polymorphisms and association with autoimmune disease. 2005 , 35, 3020-9		9

573	Cancer pharmacogenomics: international trends. 2005 , 10, 5-13	20
572	Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. 2005 , 25, 309-13	31
571	Clinical Studies of Immunotherapy With Rituximab (Rituxan [®]) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin [®]) in B-Cell Lymphoid Malignancies. 2005 , 677-709	
570	Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. 2005 , 39, S565-8	32
569	A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. 2005 , 14, 633-7	20
568	Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. 2005 , 175, 2174-83	110
567	Polymorphisms in Fc gamma RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. 2005 , 23, 474-81	219
566	Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. 2005 , 5 Suppl 1, S29-36	17
565	Genetic polymorphisms in sepsis. 2005 , 6, S61-73	78
564	Fc gamma RIIa-131R allele and Fc gamma RIIa-176V/V genotype are risk factors for progression of IgA nephropathy. 2005 , 20, 2439-45	25
563	Natural killer cell-based immunotherapeutic strategies. 2005 , 7, 16-22	38
562	Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. 2005 , 11, 2327-36	156
561	A functional variant of Fc gamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies. 2005 , 7, R1183-8	10
560	Rituximab for the treatment of diffuse large B-cell lymphomas. 2006 , 6, 1175-86	31
559	An engineered human IgG1 antibody with longer serum half-life. 2006 , 176, 346-56	264
558	Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. 2006 , 140, 777-83	32
557	Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). 2006 , 281, 23514-24	394
556	Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. <i>Blood</i> , 2006 , 107, 4669-77	2.2 60

555	Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. 2006 , 47, 703-5	5
554	Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. 2006 , 19, 259-69	52
553	Fc gamma receptor polymorphisms and periodontal status: a prospective follow-up study. 2006 , 33, 691-8	22
552	The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease. 2007 , 147, 106-11	25
551	Potent antibody therapeutics by design. 2006 , 6, 343-57	878
550	Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. 2006 , 93, 851-61	254
549	Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. 2006 , 24, 47-55	17
548	Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. 2006 , 98, 1292-301	137
547	Development of antibodies and chimeric molecules for cancer immunotherapy. 2006 , 90, 83-131	36
546	FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. 2006 , 24, 2885-90	98
545	Modulation of the effector functions of a human IgG1 through engineering of its hinge region. 2006 , 177, 1129-38	113
544	Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies. 2006 , 7, 961-4	2
543	The carbohydrate at Fc gamma RIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. 2006 , 281, 5032-6	276
542	Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. 2007 , 67, 11991-9	172
541	Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. 2007 , 178, 6596-603	149
540	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. 2007 , 7, 257-73	18
539	A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. 2007 , 13, 1875-82	92
538	A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. 2007 , 12, 1084-95	121

537	Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. 2007 , 45, 513-8		29
536	Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. <i>Blood</i> , 2007 , 110, 2561-4		193
535	Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. <i>Blood</i> , 2007 , 110, 4370-2	2.2	95
534	High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). 2007 , 257, 47-55		41
533	Enhanced binding affinity for Fc{gamma}RIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. 2007 , 44, 3122-31		130
532	High synovial expression of the inhibitory Fc{gamma}RIIb in rheumatoid arthritis. 2007 , 9, R51		35
531	Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. 2007 , 67, 3927-35		77
530	Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. 2007 , 7, 286-90		27
529	CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. 2007 , 48, 2424-36		29
528	Antibody therapeutics: isotype and glycoform selection. 2007 , 7, 1401-13		235
527	BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. 2007 , 56, 1464-77		166
526	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGR3 genes in inflammatory bowel disease: a meta-analysis. 2007 , 13, 1212-9		32
525	Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. 2007 , 136, 237-48		27
524	Improving the efficacy of trastuzumab in breast cancer. <i>Cancer Science</i> , 2007 , 98, 767-71	6.9	7
523	The role of genetic polymorphisms in periodontitis. 2007 , 43, 102-32		154
522	Pharmacogenetics of EGFR and VEGF inhibition. 2007 , 12, 1054-60		40
521	In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. 2007 , 2, 700-8		81
520	Fc receptor genes and the systemic lupus erythematosus diathesis. 2007 , 40, 567-81		54

519	Antibody targeting of B-cell maturation antigen on malignant plasma cells. 2007 , 6, 3009-18	69
518	Relevance of the low-affinity type of the Fc γ 3-receptor IIIa-polymorphism in bullous pemphigoid. 2007 , 299, 163-4	16
517	Fc γ 3RIIIa-V/F 158 polymorphism in Turkish children with asthma bronchiale and allergic rhinitis. 2008 , 19, 20-4	7
516	A human anti-D monoclonal antibody selected for enhanced Fc γ 3RIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. 2008 , 141, 109-19	40
515	Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of Fc γ 3RIIIa genetic polymorphism. 2008 , 65, 60-8	8
514	NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. 2008 , 36, 69-77	58
513	Fc γ 3RIIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. 2008 , 183, 35-40	37
512	[Pharmacogenetics in oncology]. 2008 , 131, 184-95	0
511	Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. 2008 , 7, 1490-9	125
510	Tandemly repeated Fc domain augments binding avidities of antibodies for Fc γ 3 receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. 2008 , 45, 2752-63	18
509	IFN- γ treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes. 2008 , 39, 37-44	2
508	Complement and cellular cytotoxicity in antibody therapy of cancer. 2008 , 8, 759-68	64
507	Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. 2008 , 47, 10294-304	84
506	Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. 2008 , 35, 2129-35	34
505	Fc γ 3RIIIa expression is not increased on natural killer cells expressing the Fc γ 3RIIIa-158V allotype. 2008 , 68, 976-80	38
504	A novel subset of NK cells expressing high levels of inhibitory Fc γ 3RIIB modulating antibody-dependent function. 2008 , 84, 1511-20	32
503	Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance. 2008 , 37-81	1
502	Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains. 2009 , 22, 175-88	7

501	Treating multiple sclerosis with monoclonal antibodies. 2008 , 8, 433-55		30
500	Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. 2008 , 26, 2725-31		69
499	Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. 2008 , 26, 1789-96		784
498	Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. <i>Blood</i> , 2008 , 111, 1029-38	2.2	167
497	Physiologic IgG Biodistribution, Transport, and Clearance: Implications for Monoclonal Antibody Products. 241-276		9
496	Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma. 2008 , 93, 1265-7		11
495	Pharmacokinetic properties of rituximab. 2008 , 3, 22-30		12
494	Infectious Diseases in the Pediatric Intensive Care Unit. 2008 ,		0
493	Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. 2009 , 68, 1547-52		77
492	The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs. 2010 , 26, 1-42		13
491	Impact of Fc{gamma}RIIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. 2009 , 27, 1122-9		425
490	Resistance to Trastuzumab in Breast Cancer. 2009 , 15, 7479-7491		299
489	Pharmacokinetic study and Fc{gamma}Receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. 2009 , 19, 329-333		17
488	Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. 2009 , 1, 1015-24		1
487	In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. 2009 , 15, 3376-83		24
486	Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. 2009 , 76, 458-63		26
485	Pharmacogenetics of breast cancer therapies. 2009 , 18 Suppl 3, S59-63		10
484	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. 2009 , 30, E640-50		119

483	Pharmacogenetics in chemotherapy of colorectal cancer. 2009 , 23, 257-73		10
482	Fcγ3 polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 997-1006	7.4	91
481	Functional and clinical consequences of Fc receptor polymorphic and copy number variants. 2009 , 157, 244-54		119
480	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. 2009 , 68, 561-73		17
479	Fcγ receptors: structure, function and role as genetic risk factors in SLE. 2009 , 10, 380-9		91
478	Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. 2009 , 100, 113-7		59
477	Association of the leukocyte immunoglobulin G (Fcγ) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients. 2009 , 73, 586-9		4
476	Mécanismes de l'action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets. 2009 , 76, 826-832		2
475	Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. 2009 , 68, 1775-80		42
474	Science and Practice of Pediatric Critical Care Medicine. 2009 ,		1
473	Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. <i>Blood</i> , 2009 , 113, 3716-25	2.2	938
472	FCGR3A polymorphism story: a new piece of the puzzle. 2009 , 50, 1401-2		6
471	Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. 2009 , 50, 1361-8		19
470	Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. 2009 , 50, 723-7		31
469	Glycosylation of Therapeutic IgGs. 67-89		9
468	Engineering the Antibody Fc Region for Optimal Effector Function. 349-370		3
467	Optimization of Fc Domains to Enhance Antibody Therapeutics. 124-143		
466	Glycoengineered Therapeutic Antibodies. 144-154		2

465	The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcγIIIa-48L/R/H polymorphism. 2010 ,		
464	Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. <i>Blood</i> , 2010 , 115, 3960-5	2.2	14
463	Effect of FCGR2A and FCGR3A variants on CLL outcome. <i>Blood</i> , 2010 , 116, 4212-22	2.2	48
462	[Enhancement of antibody-dependent cellular cytotoxicity by tandem Fc multimerization]. 2010 , 130, 49-54		0
461	The rules of variation: amino acid exchange according to the rotating circular genetic code. 2010 , 264, 711-21		16
460	Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. 2010 , 46, 192-205		13
459	Anti-CD30 Antibodies for Hodgkin lymphoma. 2010 , 5, 140-7		38
458	Expression of human FcγRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. 2010 , 354, 20-33		15
457	Carrageenan from <i>Solieria chordalis</i> (Gigartinales): Structural analysis and immunological activities of the low molecular weight fractions. 2010 , 81, 448-460		88
456	Fcγ receptor polymorphisms and their association with periodontal disease: a meta-analysis. 2010 , 37, 255-65		35
455	[Implications of receptors for the Fc portion of IgG (FcγRs) in mechanism of action of therapeutic antibodies]. 2010 , 97, 511-22		5
454	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. 2010 , 69, 1054-7		52
453	The levels of CD16/Fc gamma receptor IIIA on CD14+ CD16+ monocytes are higher in children with severe Plasmodium falciparum anemia than in children with cerebral or uncomplicated malaria. 2010 , 78, 2173-81		19
452	Germline genetic variation, cancer outcome, and pharmacogenetics. 2010 , 28, 4029-37		56
451	Unresolved issues in diffuse large B-cell lymphomas. 2010 , 10, 387-402		4
450	Antibodies in cancer immunotherapy. 2010 , 6, 291-305		2
449	Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. 2010 , 16, 2184-93		9
448	Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2010 , 10, 347-52		13

447	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. 2010 , 46, 1829-34	67
446	Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. 2010 , 37, 257-64	26
445	CD20-targeted therapy: the next generation of antibodies. 2010 , 47, 199-210	77
444	Rituximab: mechanism of action. 2010 , 47, 115-23	519
443	Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab. 2010 , 19 Suppl 1, S41-50	25
442	FcRIIA and FcRIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. 2011 , 52, 1604-6	13
441	Chemoenzymatic synthesis and Fcγreceptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIa receptor. 2011 , 133, 18975-91	115
440	Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. 2011 , 2, 369-81	2
439	Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity. 2011 , 6, 1575-91	16
438	NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. 2011 , 24, 359-68	53
437	Principles of Anticancer Drug Development. 2011 ,	
436	Host genetics in follicular lymphoma. 2011 , 24, 121-34	9
435	Rituximab resistance. 2011 , 24, 203-16	147
434	Novel antibodies against follicular non-Hodgkin's lymphoma. 2011 , 24, 231-56	18
433	Molecular engineering to improve antibodies' anti-lymphoma activity. 2011 , 24, 217-29	17
432	FcRIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. 2011 , 58, 263-70	15
431	FcRIIIa (CD16) induction on human T lymphocytes and CD16pos T-lymphocyte amplification. 2011 , 34, 542-9	8
430	Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. <i>Blood</i> , 2011 , 117, 1483-91	2.2 27

429	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. <i>Blood</i> , 2011 , 118, 3347-9	2.2	93
428	Genetic polymorphism of Fcγ receptors IIa, IIIa and IIIb in South Indian patients with generalized aggressive periodontitis. 2011 , 53, 467-74		12
427	Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. <i>Cancer Science</i> , 2011 , 102, 432-8	6.9	23
426	A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. 2011 , 152, 721-6		27
425	Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. 2011 , 154, 223-8		50
424	Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. 2011 , 166, 361-5		19
423	Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. 2011 , 39, 1064-71		26
422	An overview on the genetic of rheumatoid arthritis: a never-ending story. 2011 , 10, 599-608		122
421	An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. 2011 , 19, 101-13		206
420	The impact of Fcγ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. <i>Blood</i> , 2011 , 118, 4657-62	2.2	51
419	Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. 2011 , 126, 497-505		23
418	Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. 2011 , 126, 247-8; author reply 248		
417	TNF receptor II fusion protein with tandemly repeated Fc domains. 2011 , 149, 337-46		7
416	Optimizing therapeutic antibody function: progress with Fc domain engineering. 2011 , 25, 1-11		47
415	Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. 2011 , 2011, 352182		68
414	Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. 2011 , 2011, 379123		104
413	Interindividual variability of response to rituximab: from biological origins to individualized therapies. 2011 , 17, 19-30		69
412	Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma. 2011 , 34, 322-4		0

411	Current Technological Development of Antibody Therapeutics. 2011 , 11, 21-32	1
410	Molecular and functional characterization of cynomolgus monkey IgG subclasses. 2011 , 186, 341-9	32
409	Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. 2011 , 79, 3388-96	14
408	FcR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. 2011 , 22, 1302-1307	135
407	Antigens. 2011 , 1-157	0
406	A single-nucleotide polymorphism of the Fcγreceptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. 2011 , 46, 238-43	13
405	The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. 2012 , 23, 45-50	14
404	HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells. 2012 , 41, 831-46	1
403	Genetic polymorphisms of FcR1IIa and FcR1IIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. 2012 , 82, 83-9	18
402	Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcR1IIa-genotyped patients with previously treated follicular lymphoma. 2012 , 18, 1395-403	51
401	Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. 2012 , 4, 532-41	24
400	Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. 2012 , 31, 1671-7	13
399	ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. 2012 , 83, 218-27	18
398	FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-β blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. 2012 , 39, 1035-41	26
397	Analysis of Fcγreceptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. 2012 , 18, 3478-86	89
396	Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. 2012 , 4, 310-8	65
395	Fcγreceptor gene polymorphisms in childhood immune thrombocytopenic purpura. 2012 , 34, 349-52	7
394	Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. 2012 , 97, 1686-94	27

393	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. 2012 , 97, 937-42		51
392	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012 , 120, 2650-7	2.2	47
391	Polymorphisms in the Fc gamma receptor IIIA and Toll-like receptor 9 are associated with protection against severe malarial anemia and changes in circulating gamma interferon levels. 2012 , 80, 4435-43		11
390	Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. 2012 , 53, 1945-8		10
389	Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. 2012 , 109, 18030-5		289
388	Obinutuzumab for the treatment of lymphoproliferative disorders. 2012 , 12, 343-51		29
387	Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. 2012 , 188, 4405-11		78
386	Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. 2012 , 86, 8672-80		86
385	Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. 2012 , 134, 12308-18		210
384	Isotype and glycoform selection for antibody therapeutics. 2012 , 526, 159-66		200
383	Epistatic interactions between Fc (GM) and FcR genes and the host control of human immunodeficiency virus replication. 2012 , 73, 263-6		17
382	The interactions of therapeutic antibodies with Fc receptors. 2012 , 143, 20-7		19
381	Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. 2012 , 42, 1113-9		20
380	RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. 2012 , 8, 687-95		30
379	Breast Cancer Pharmacogenetics in the Era of Personalized Medicine. 2012 , 4, 271-281		3
378	Evidence for therapeutic drug monitoring of targeted anticancer therapies. 2012 , 30, 4017-25		144
377	Association of Fcγ receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients. <i>PLoS ONE</i> , 2012 , 7, e42439	3.7	36
376	Immunotherapy for B-cell lymphoma: current status and prospective advances. <i>Frontiers in Immunology</i> , 2012 , 3, 3	8.4	14

375	Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. 2012 , 11, 311-31		232
374	Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study. 2012 , 32, 2203-7		0
373	Genetic polymorphism studies in periodontitis and Fcγ receptors. 2012 , 47, 273-85		28
372	An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. 2012 , 50, 134-41		46
371	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. 2012 , 73, 597-605		19
370	Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. 2012 , 73, 776-85		26
369	Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. 2012 , 158, 539-47		30
368	Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. 2012 , 18, 43-8		16
367	The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. <i>Leukemia</i> , 2013 , 27, 190-201	10.7	42
366	Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis. 2013 , 40, 4985-93		11
365	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013 ,	0.3	1
364	FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. 2013 , 65, 265-71		59
363	A novel FCGR3A intragenic haplotype is associated with increased FcγIIIa/CD16a cell surface density and population differences. 2013 , 74, 627-34		9
362	Role of non-HLA gene polymorphisms in graft-versus-host disease. 2013 , 98, 309-18		13
361	Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. 2013 , 24, 362-8		20
360	RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. 2013 , 73, 683-94		46
359	Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. 2013 , 60, 972-8		40
358	A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. 2013 , 6, 1		230

357	Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. 2013 , 5, 22-33		193
356	Monoclonal antibodies in oncology therapeutics: present and future indications. 2013 , 13, 269-82		19
355	Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. 2013 , 84, 1025-33		87
354	Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with α -fucosylated anti-CD19 humanized antibodies. <i>Leukemia</i> , 2013 , 27, 1263-74	10.7	34
353	At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. 2013 , 43, 1383-8		15
352	Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. 2013 , 4, e00573-13		41
351	Generation and preclinical characterization of a Fc-optimized GTR-Ig fusion protein for induction of NK cell reactivity against leukemia. 2013 , 21, 877-86		13
350	Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. <i>Frontiers in Immunology</i> , 2013 , 4, 76	8.4	154
349	Antibody Glycosylation and Inflammation. 2013 , 2, 392-414		74
348	A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. 2013 , 36, 331-41		21
347	A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 631-5	1.9	4
346	The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. 2013 , 14, 1032-8		34
345	FcRIIIa and FcRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. 2013 , 24, 35-9		13
344	Research Highlights: Highlights from the latest research in rheumatoid arthritis pharmacogenomics. 2013 , 14, 857-860		1
343	Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis. 2013 , 19, 2061-8		9
342	Association of FcRIIIa-158V/F with systemic lupus erythematosus in a Chinese population. 2013 , 16, 685-91		5
341	Abnormalities in Immune Complex Clearance and Fc Receptor Function. 2013 , 127-140		1
340	No Mechanism is an Island. 2014 , 257-267		

339	Structural Recognition of Immunoglobulins by FcγReceptors. 2014 , 131-144		3
338	A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. 2014 , 6, 728-39		85
337	Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art. <i>Frontiers in Immunology</i> , 2014 , 5, 577	8.4	16
336	FcγReceptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder. 2014 , 2014, 264723		3
335	Single-nucleotide polymorphisms and copy number variations of the and genes in healthy Japanese subjects. 2014 , 2, 265-269		6
334	Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. 2014 , 2014, 965384		10
333	FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. 2014 , 33, 616-23		11
332	Advances in Tumor Immunology and Immunotherapy. 2014 ,		0
331	Fc Protein Engineering. 2014 , 297-316		1
330	FcγReceptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans. 2014 , 66, 1291-9		23
329	IgE-based immunotherapy of cancer: challenges and chances. 2014 , 69, 137-49		23
328	Pharmacogenomics of biological treatment in rheumatoid arthritis. 2014 , 14, 157-64		7
327	Fc receptors as adaptive immunoreceptors. 2014 , 382, 131-64		29
326	Human FcR polymorphism and disease. 2014 , 382, 275-302		27
325	Obinutuzumab: a new class of anti-CD20 monoclonal antibody. 2014 , 26, 484-91		31
324	Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 26-34	1.9	9
323	Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques. 2014 , 18, 665-73		4
322	FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease. 2014 , 20, 4511-9		7

321	Clinical Development of Antibody-Fusion Proteins for Cancer Therapy. 2014 , 213-235	
320	IgG-effector functions: "the good, the bad and the ugly". 2014 , 160, 139-44	54
319	Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer. 2014 , 239-255	5
318	Targeting the Fc receptor in autoimmune disease. 2014 , 18, 335-50	43
317	A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. <i>Blood</i> , 2014 , 123, 471-80.2	135
316	Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297. 2014 , 103, 1613-1627	27
315	Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. 2014 , 44, 2331-9	18
314	Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. <i>Leukemia</i> , 2014 , 28, 2213-21	10.7 106
313	T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. 2014 , 74, 93-103	131
312	Gene-modified human $\gamma\delta$ T cells expressing a chimeric CD16-CD3 ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy. 2014 , 2, 249-62	27
311	Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. 2014 , 414, 69-81	55
310	The challenge of indication extrapolation for infliximab biosimilars. 2014 , 42, 177-83	120
309	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. 2014 , 14, 14-9	17
308	Fc Receptors. 2014 ,	8
307	Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. 2014 , 34, 1409-15	27
306	The 158VV Fc γ receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. 2014 , 73, 716-21	42
305	Fc γ R and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. 2014 , 18, 541-8	8
304	Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. 2014 , 407, 63-75	36

303	Fc r�cepteur et polynucl�aire neutrophile. 2014 , 2014, 39-46		
302	Resistance to human epidermal growth factor receptor type 2-targeted therapies. 2014 , 50, 892-901		37
301	Targeting CD137 enhances the efficacy of cetuximab. 2014 , 124, 2668-82		137
300	Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. <i>Blood</i> , 2014 , 124, 3241-9	2.2	70
299	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcRIIIA/FcRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. 2015 , 13, 324		30
298	Development of a bispecific antibody tetramerized through hetero-associating peptides. 2015 , 282, 4389-401		8
297	Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients. 2015 , 99, 1907-11		7
296	Structural analysis of Fc/FcR complexes: a blueprint for antibody design. <i>Immunological Reviews</i> , 2015 , 268, 201-21	11.3	43
295	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. 2015 , 7, 319-30		3
294	NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015 , 6, 368	8.4	288
293	A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. <i>PLoS ONE</i> , 2015 , 10, e0144712	3.7	29
292	Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. 2015 , 4, 91-100		32
291	In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. 2015 , 2015, 482089		15
290	Monoclonal Antibodies for the Treatment of Cancer. 2015 , 683-694.e3		
289	Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. 2015 , 55, 553-62		32
288	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. 2015 , 54, 551-62		43
287	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. 2015 , 100, 263-8		82
286	An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. 2015 , 136, 1073-84		27

285	Monoclonal Antibodies for Cancer Immunotherapy. 2015 , 293-328		2
284	Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. 2015 , 194, 2715-24		81
283	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. 2015 , 135-183		
282	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. 2015 , 10, 791-808		7
281	Mechanisms of action of therapeutic antibodies for cancer. 2015 , 67, 28-45		98
280	Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. 2015 , 104, 1866-1884		226
279	Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcRIIIa patients with previously treated follicular lymphoma. 2015 , 56, 42-8		23
278	Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. 2015 , 3, 567-74		28
277	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 2015 , 89, 9952-61		44
276	Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma. 2015 , 56, 3257-66		3
275	Fc gamma receptors: glycobiology and therapeutic prospects. 2016 , 9, 209-219		50
274	Manufacturing Natural Killer Cells as Medicinal Products. <i>Frontiers in Immunology</i> , 2016 , 7, 504	8.4	25
273	Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. 2016 , 14, 239		6
272	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. <i>Oncotarget</i> , 2016 , 7, 86359-86373	3.3	99
271	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. 2016 , 16, 472-7		13
270	Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications After Liver Transplantation. <i>American Journal of Transplantation</i> , 2016 , 16, 625-33	8.7	17
269	Fc gamma receptor IIIa polymorphism is not associated with susceptibility to systemic lupus erythematosus in Brazilian patients. 2016 , 56, 515-520		1
268	Harnessing Fc receptor biology in the design of therapeutic antibodies. 2016 , 40, 78-87		49

267	The impact of and gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients. <i>Oncology Letters</i> , 2016 , 11, 3332-3336	2.6	1
266	Development of Engineered T Cells Expressing a Chimeric CD16-CD3 ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia. 2016 , 22, 4405-16		15
265	Comparing high-throughput methods to measure NK cell-mediated antibody dependent cellular cytotoxicity during HIV-infection. 2016 , 434, 46-52		8
264	Polimorfismo do receptor Fc gama IIIa n \bar{b} est \bar{a} associado \hat{a} susceptibilidade ao l \bar{p} us eritematoso sist \bar{e} mico em pacientes brasileiros. 2016 , 56, 515-520		2
263	Identification of high-affinity anti-CD16A allotype-independent human antibody domains. 2016 , 101, 281-289		8
262	Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. 2016 , 113, 71-80		15
261	Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity. <i>Cancer Science</i> , 2016 , 107, 674-81	6.9	11
260	NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1325-1335	7.4	7
259	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. 2016 , 90, 8644-60		13
258	SNPs rs4656317 and rs12071048 located within an enhancer in FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell-mediated ADCC by transcriptional regulation. 2016 , 77, 997-1003		6
257	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 2016 , 90, 10362-10378		15
256	The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. 2016 , 95, 1483-90		15
255	Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells. 2016 , 1441, 43-56		4
254	The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity. 2016 , 434, 16-23		21
253	Pharmacogenetic Predictors of Response. 2016 , 882, 191-215		3
252	Novel Biomarkers in the Continuum of Breast Cancer. 2016 ,		9
251	Distribution of Fc γ R gene polymorphisms among two sympatric populations in Mali: differing allele frequencies, associations with malariometric indices and implications for genetic susceptibility to malaria. 2016 , 15, 29		13
250	Scientific Significance of Clinically Insignificant Fc γ IIIa-V158F Polymorphism. 2016 , 22, 787-9		4

249	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. 2016 , 90, 4951-4965	21
248	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. 2016 , 22, 821-6	21
247	Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. 2016 , 55, 939-48	42
246	The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcR3a-V158F genotypes in healthy Japanese subjects. 2016 , 77, 165-71	19
245	Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. 2016 , 13, 391-400	37
244	A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. 2016 , 97, 275-90	58
243	Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. 2016 , 23, 624-32	7
242	Tricking the balance: NK cells in anti-cancer immunity. 2017 , 222, 11-20	111
241	Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. 2017 , 188, 275-282	19
240	How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. 2017 , 31, 235-249	7
239	Precision immunomedicine. 2017 , 6, e25	2
238	Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events. 2017 , 27, 391-395	20
237	Thaw-and-use target cells pre-labeled with calcein AM for antibody-dependent cell-mediated cytotoxicity assays. 2017 , 447, 37-46	9
236	Fc Gamma R. 2017 , 209-228	
235	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. 2017 , 8, 15711	94
234	Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients. 2017 , 78, 357-362	6
233	Rhlg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance. <i>Blood</i> , 2017 , 129, 1045-1048	2.2 11
232	Low copy numbers of FCGR3A and FCGR3B associated with Chinese patients with SLE and AASV. 2017 , 26, 1383-1389	9

231	Characterization of Fc γ RIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells. 2017 , 441, 56-66	22
230	FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. 2017 , 152, 169-179	8
229	Rapid screening of IgG quality attributes - effects on Fc receptor binding. 2017 , 7, 1557-1574	14
228	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor Fc γ RI Reduce Immune Complex Binding and Downstream Effector Functions. 2017 , 199, 2432-2439	5
227	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. 2017 , 24,	22
226	Pediatric Sepsis: Genetic Considerations. 2017 , 07, e76-e88	1
225	Effect of Fc γ Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation. 2017 , 3, e164	9
224	Association between Fc γ Receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya. 2017 , 17, 289	10
223	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. 2017 , 19, 44	6
222	Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. 2017 , 28, 415-420	7
221	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. 2017 , 56, 635-647	16
220	An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. <i>Leukemia</i> , 2017 , 31, 459-469	10.7 33
219	Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. 2017 , 56, 317-337	34
218	Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. <i>Oncology Letters</i> , 2018 , 15, 2604-2610	2.6 7
217	Effects of FCGR3A-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab. 2017 , 125, 1102-1107	2
216	Effect of Fc γ Receptor 3a (γ) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. 2017 , 3, e000485	11
215	Application of Lectin Array Technology for Biobetter Characterization: Its Correlation with Fc γ RIII Binding and ADCC. 2016 , 6,	8
214	FC γ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. <i>Frontiers in Immunology</i> , 2017 , 8, 457	8.4 30

213	Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017 , 8, 1544	8.4	38
212	Gradual Increase of FcR11a/CD16a Expression and Shift toward IFN- γ Secretion during Differentiation of CD56 Natural Killer Cells. <i>Frontiers in Immunology</i> , 2017 , 8, 1556	8.4	2
211	Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. 2018 , 10, e2018014		11
210	and polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 5065-5076	4.4	6
209	Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcR11a-F158V Genotypes. 2017 , 06,		0
208	The PI3K β Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. 2018 , 200, 2304-2312		12
207	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. 2018 , 14, 197-206		21
206	Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fc γ receptors. 2018 , 197, 1-8		15
205	Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. <i>American Journal of Transplantation</i> , 2018 , 18, 2261-2273	8.7	23
204	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. 2018 , 93, 436-447		14
203	New Trends in Drug Discovery. 2018 , 1-39		
202	Restricted processing of CD16a/Fc γ receptor IIIa -glycans from primary human NK cells impacts structure and function. 2018 , 293, 3477-3489		42
201	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β 2018 , 10,		239
200	NKG2C Deletion Is a Risk Factor for Human Cytomegalovirus Viremia and Disease After Lung Transplantation. 2018 , 217, 802-806		10
199	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. 2018 , 33, 649-663.e4		296
198	Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. 2018 , 36, 76-83		7
197	Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. 2018 , 9, 47-62		101
196	Pharmacogenetic biomarkers of response in Crohn's disease. 2018 , 18, 1-13		8

195	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. 2018 , 128, 1419-1427		10
194	The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura. 2018 , 23, 169-174		0
193	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. 2018 , 19, 209-222		24
192	Receptor Tyrosine Kinase-Targeted Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	103
191	A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. 2018 , 8, 15983		24
190	Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 2873	8.4	19
189	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. <i>Frontiers in Immunology</i> , 2018 , 9, 2134	8.4	128
188	A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. 2018 , 293, 19899-19908		16
187	-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. 2018 , 21, 45-50		
186	Differential regulation of human monocytes and NK cells by antibody-opsonized tumors. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1239-1250	7.4	1
185	Fc γ IIIa-dependent IFN- γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety. 2018 , 10, 913-921		4
184	Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. <i>Frontiers in Immunology</i> , 2017 , 8, 1825	8.4	19
183	Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. <i>Frontiers in Immunology</i> , 2017 , 8, 1899	8.4	11
182	Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. <i>MSphere</i> , 2018 , 3,	5	13
181	Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. 2018 , 15, 24		
180	The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. 2018 , 10, 693-711		114
179	Fc γ receptor-mediated influx of S100A8/A9-producing neutrophils as inducer of bone erosion during antigen-induced arthritis. 2018 , 20, 80		8
178	Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. 2018 , 19, 1229-1238		45

177	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. 2018 , 92,		27
176	Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. <i>Frontiers in Immunology</i> , 2019 , 10, 1296	8.4	126
175	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. 2019 , 14, 426-438		8
174	Genetic Variation in Low-To-Medium-Affinity FcγReceptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine. <i>Frontiers in Immunology</i> , 2019 , 10, 2237	8.4	32
173	Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. 2019 , 7, 1633-1646		13
172	Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. 2019 , 11, 1341-1350		19
171	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. <i>Frontiers in Immunology</i> , 2018 , 9, 3163	8.4	13
170	The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. 2019 , 12, 1756284819852535		6
169	Redirected optimized cell killing (ROCK ²): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. 2019 , 11, 899-918		22
168	Fc-gamma receptors and S100A8/A9 cause bone erosion during rheumatoid arthritis. Do they act as partners in crime?. 2019 , 58, 1331-1343		7
167	High Numbers of Circulating CD57 NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2 Primary Breast Cancer. 2019 , 7, 1280-1292		15
166	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. 2019 , 93,		7
165	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. 2019 , 93,		5
164	Human FcγReceptors compete for TGN1412 binding that determines the antibody's effector function. 2019 , 49, 1117-1126		5
163	From the "missing self" hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance. 2019 , 105, 955-971		9
162	A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. 2019 , 28, 900-909		16
161	Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant. <i>Frontiers in Immunology</i> , 2019 , 10, 735	8.4	2
160	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 176	5.3	45

159	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. 2019 , 93,		14
158	Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 548	8.4	99
157	Fc γ RIIIA-mediated activation of NK cells by IgG heavy chain complexed with MHC class II molecules. 2019 , 31, 303-314		3
156	Fc γ R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019 , 10, 292	8.4	58
155	Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. 2019 , 105, 1297-1303		33
154	Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study. <i>MSphere</i> , 2019 , 4,	5	3
153	Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity. 2019 , 203, 3126-3135		23
152	Fc γ RIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV. 2019 , 19, 1053		5
151	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer. 2019 , 21, 133		15
150	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. 2019 , 8,		22
149	Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1. 2019 , 9, 6		10
148	Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region. 2019 , 464, 87-94		2
147	Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. 2019 , 35, 310-325		9
146	Cancer Immunotherapy: The Dawn of Antibody Cocktails. 2019 , 1904, 11-51		14
145	Polymorphism of FCGR3A gene in chronic beryllium disease. 2019 , 20, 493-499		4
144	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. 2019 , 184, 475-479		14
143	Frequency analysis of the g.7081T>G/A and g.10872T>G polymorphisms in the FCGR3A gene (CD16A) using nested PCR and their functional specific effects. 2019 , 20, 39-45		3
142	Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. 2020 , 21, 72-80		10

141	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. 2020 , 59, 7-23		
140	An update on genetic susceptibility in lupus nephritis. 2020 , 210, 108272		11
139	The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	14
138	NK cells for cancer immunotherapy. 2020 , 19, 200-218		310
137	Differentiation and adaptation of natural killer cells for anti-malarial immunity. <i>Immunological Reviews</i> , 2020 , 293, 25-37	11.3	5
136	The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. 2020 , 17, 1768-1784		5
135	Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). 2020 , 9,		1
134	Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. 2020 , 68, 79-91		8
133	Polymorphisms in Fc Gamma Receptors and Susceptibility to Malaria in an Endemic Population. <i>Frontiers in Immunology</i> , 2020 , 11, 561142	8.4	4
132	Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. 2020 , 55, 132-140		2
131	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. 2020 , 11,		2
130	HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. <i>MSphere</i> , 2020 , 5,	5	6
129	Overcoming hypoxia-induced functional suppression of NK cells. 2020 , 8,		22
128	Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide. 2020 , 374, 93-103		16
127	Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. 2020 , 26, 4494-4502		13
126	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. 2020 , 149, 102927		7
125	Engineering a human IgG2 antibody stable at low pH. 2020 , 29, 1186-1195		3
124	Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca mobilization and cytotoxicity in human NK cells. 2020 , 108, 1409-1423		1

123	Quantitative analysis of human NK cell reactivity using latex beads coated with defined amounts of antibodies. 2020 , 50, 656-665		3
122	Human genetics of meningococcal infections. 2020 , 139, 961-980		12
121	Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes. 2020 , 30, 427-432		6
120	Boosting with AIDS VAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. 2020 , 94,		13
119	An update on genetic susceptibility in lupus nephritis. 2020 , 215, 108389		3
118	The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients - a retrospective study. 2020 , 33, 936-947		2
117	Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma. 2020 , 9,		13
116	Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. <i>Blood</i> , 2020 , 135, 399-410	2.2	68
115	Fcγ receptors in autoimmunity and end-organ damage. 2021 , 179-195		
114	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021 , 137, 1154-1165	2.2	18
113	Evidence for altered host genetic factors in KSHV infection and KSHV-related disease development. 2021 , 31, e2160		7
112	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. 2021 , 27, 2179-2189		30
111	Elotuzumab. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2021 , 73-82	0.3	
110	Use of 5-Thio-L-Fucose to modulate binding affinity of therapeutic proteins. 2021 , 118, 1818-1831		4
109	Genetic Influences in Breast Cancer Drug Resistance. 2021 , 13, 59-85		3
108	Cellular and Molecular Crosstalk of Graft Endothelial Cells During AMR: Effector Functions and Mechanisms. 2021 , 105, e156-e167		3
107	The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System. 2021 , 39, 285-296		1
106	References. 2021 , 301-427		

105	Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. 2021 , 11,		10
104	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. 2021 , 10,		3
103	Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity. 2021 , 143, 7828-7838		6
102	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. <i>Cancers</i> , 2021 , 13,	6.6	3
101	Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease. 2021 , 14, 2184-2192		2
100	Factor VIII-Fc Activates Natural Killer Cells Fc-Mediated Interactions With CD16. <i>Frontiers in Immunology</i> , 2021 , 12, 692157	8.4	0
99	Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. 2021 , 1		
98	A functional mammalian display screen identifies rare antibodies that stimulate NK cell-mediated cytotoxicity. 2021 , 118,		
97	An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR. 2021 , 73, 539-553		0
96	Switched phenotypes of macrophages during the different stages of <i>Schistosoma japonicum</i> infection influenced the subsequent trends of immune responses. 2021 ,		1
95	FcγRIIIa and FcγRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia. 2021 ,		
94	Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. 2021 , 5, 2935-2944		0
93	The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
92	On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation. 2021 , 4, 1031		1
91	Significant differences in FcγRIIIa, FcγRIIIa and FcγRIIIb genes polymorphism and anti-malarial IgG subclass pattern are associated with severe <i>Plasmodium falciparum</i> malaria in Saudi children. 2021 , 20, 376		0
90	Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era. 2021 , 60, 15-25		5
89	Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells. <i>Cancers</i> , 2021 , 13,	6.6	13
88	Obstacles and opportunities in the clinical development of targeted therapeutics. 2005 , 63, 19-41		10

87	Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab. 2017 , 16, 1770-1788		43
86	SHIV.CH505-infected infant and adult rhesus macaques exhibit similar HIV Env-specific antibody kinetics, despite distinct T-follicular helper (Tfh) and germinal center B cell landscapes.		1
85	Optimized Mucosal MVA Prime/ Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen.		1
84	Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity.		1
83	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. 2019 , 4,		17
82	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. 2020 , 5,		11
81	A family with complement factor D deficiency. 2001 , 108, 233-240		76
80	Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. <i>Blood</i> , 2002 , 100, 1765-1773	2.2	94
79	Variant genotypes of Fc γ RIIIA influence the development of Kaposi's sarcoma in HIV-infected men. <i>Blood</i> , 2000 , 95, 2386-2390	2.2	3
78	Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. <i>PLoS ONE</i> , 2013 , 8, e83905	3.7	16
77	The c.503T>C Polymorphism in the Human KLRB1 Gene Alters Ligand Binding and Inhibitory Potential of CD161 Molecules. <i>PLoS ONE</i> , 2015 , 10, e0135682	3.7	4
76	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival. <i>PLoS ONE</i> , 2015 , 10, e0139329	3.7	6
75	IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). <i>Oncotarget</i> , 2017 , 8, 2731-2744	3.3	14
74	FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 28071-83	3.3	6
73	Platelet and Leukocyte Fc γ Receptors in Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007 , 187-208		2
72	Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. <i>Oncology Letters</i> , 2019 , 18, 4555-4562	2.6	0
71	Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation. <i>Experientia Supplementum (2012)</i> , 2021 , 112, 481-517	2.2	1
70	Vaccine-induced, high magnitude HIV Env-specific antibodies with Fc-mediated effector functions are insufficient to protect infant rhesus macaques against oral SHIV infection.		

- 69 Biological Therapy of Non-Hodgkin's Lymphomas. **2006**, 249-277
- 68 Host Genetic Susceptibility to Infection. **2008**, 225-311
- 67 Genetic Polymorphisms in Critical Care and Illness. **2009**, 1-16
- 66 Physiologic IgG Biodistribution, Transport, and Clearance: Implications for Monoclonal Antibody Products. 1 0
- 65 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461
- 64 Humoral Pathogenesis. **2011**, 365-383
- 63 Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. *Resistance To Targeted Anti-cancer Therapeutics*, **2013**, 73-92 0.3
- 62 Systemic Lupus Erythematosus and the Kidney. **2014**, 153-181
- 61 Activation of NK Cell Responses and Immunotherapy of Cancer. **2014**, 57-66
- 60 Genetic Polymorphisms in Critical Illness and Injury. **2014**, 177-202 1
- 59 Polymorphisms of Fc γ RIIIa on NK cells and macrophages. **1998**, 135-140
- 58 NK-Cell Immunotherapy for AML. **2015**, 737-755
- 57 Fc Gamma R. **2015**, 1-20
- 56 Accurate interrogation of FCGR3A rs396991 in European and Asian populations using a widely available TaqMan genotyping method. *Pharmacogenetics and Genomics*, **2015**, 25, 569-72 1.9 1
- 55 Humoral Pathogenesis. **2016**, 159-184 1
- 54 Transfection of Fc γ RIIIa (CD16) Alone Can Be Sufficient To Enable Human α CR T Lymphocytes To Mediate Antibody-Dependent Cellular Cytotoxicity. *ImmunoHorizons*, **2017**, 1, 63-70 2.7 2
- 53 Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells.
- 52 Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. **2020**, 159-212

51	Human immune polymorphisms associated with the risk of cryptococcal disease. <i>Immunology</i> , 2021 ,	7.8	1
50	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. <i>Cancers</i> , 2021 , 13,	6.6	1
49	Monoclonal Antibodies for Cancer Immunotherapy. 2021 , 273-312		1
48	Personalized Prevention Strategies to Defeat Cancer. 2021 , 41-51		
47	Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia. <i>Biology</i> , 2021 , 10,	4.9	0
46	Determining ADCC Activity of Antibody-Based Therapeutic Molecules using Two Bioluminescent Reporter-Based Bioassays. <i>Current Protocols</i> , 2021 , 1, e296		4
45	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 801124 ^{5.3}		
44	Beryllium. 2022 , 101-119		
43	Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	2
42	A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.. <i>Leukemia</i> , 2022 ,	10.7	0
41	Role of Fcγ receptors in HER2-targeted breast cancer therapy.. 2022 , 10,		6
40	Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
39	Gene-Environment interactions and metal toxicity. 2022 , 349-368		1
38	Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy.. <i>Frontiers in Immunology</i> , 2022 , 13, 822508	8.4	0
37	High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.. 2022 , 10,		0
36	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.. <i>Npj Vaccines</i> , 2022 , 7, 18	9.5	1
35	Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.. <i>Frontiers in Immunology</i> , 2022 , 13, 841859	8.4	0
34	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.. <i>MSphere</i> , 2022 , 7, e0083921 ⁵		0

33	A novel cancer-specific EGFR antibody obtained from the serum of esophageal cancer patients with long-term survival.. <i>Cancer Science</i> , 2022 ,	6.9	0
32	Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 830482	8.4	0
31	FcR11a-158V/F polymorphism affects the performance of FcR11a-related bioassay.. <i>Biochemical and Biophysical Research Communications</i> , 2022 , 608, 149-155	3.4	
30	Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.. <i>OncoTargets and Therapy</i> , 2022 , 15, 471-478	4.4	1
29	High-affinity FcR11a genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19.. <i>Genetics in Medicine</i> , 2022 ,	8.1	2
28	Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients. <i>Vaccines</i> , 2022 , 10, 725	5.3	
27	Next Generation Natural Killer Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	0
26	From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	1
25	Adoptive immunotherapy overcomes genetic susceptibility to bloodstream infections due to fc-gamma receptor polymorphisms after liver transplantation. <i>American Journal of Transplantation</i> ,	8.7	0
24	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 12,	5.3	0
23	Heterogeneity in IgG-CD16 signaling in infectious disease outcomes. <i>Immunological Reviews</i> ,	11.3	1
22	PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition. <i>Frontiers in Oncology</i> , 12,	5.3	
21	Natural killer cells: the next wave in cancer immunotherapy. <i>Frontiers in Immunology</i> , 13,	8.4	
20	Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1. 2022 , 7,		
19	Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia. 2022 , 25, 104856		
18	ADCC enhancement: A conundrum or a boon to mAb therapy?. 2022 , 79, 10-18		0
17	Human natural killer cells: form, function, and development. 2022 ,		1
16	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. 2022 , 43, 932-946		0

- 15 Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy. 82-90 ○
- 14 Breaking boundaries: Current progress of anticancer NK cell-based drug development. **2022**, 103436 ○
- 13 Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox. **2022**, 14, 5657 ○
- 12 The study of genetic predisposition on periodontitis and peri-implantitis. **2022**, 25, 1799 ○
- 11 Designing Cancer Immunotherapies That Engage T Cells and NK Cells. **2023**, 41, 1
- 10 The prospect of genetically engineering natural killer cells for cancer immunotherapy. **2022**, 11, ○
- 9 Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. **2022**, 14, 5787 ○
- 8 The natural killer cell-associated rs9916629 - C allele is a novel genetic risk factor for fatal COVID-19. **2023**, 95, ○
- 7 Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. 13, ○
- 6 A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line. **2023**, 4, 102224 ○
- 5 Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy. Publish Ahead of Print, ○
- 4 Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. **2023**, ○
- 3 Advancing cell-based cancer immunotherapy through stem cell engineering. **2023**, ○
- 2 Analysis of FCGR3A-p.176Val variants in women with recurrent pregnancy loss and the association with CD16a expression and anti-HLA antibody status. **2023**, 13, ○
- 1 Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis. ○